Humana Inc. (NYSE:HUM) Stock Position Lowered by Wilmington Savings Fund Society FSB

Wilmington Savings Fund Society FSB trimmed its position in shares of Humana Inc. (NYSE:HUM) by 3.0% during the 4th quarter, HoldingsChannel reports. The firm owned 2,901 shares of the insurance provider’s stock after selling 91 shares during the quarter. Wilmington Savings Fund Society FSB’s holdings in Humana were worth $736,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in HUM. International Assets Investment Management LLC grew its holdings in shares of Humana by 261,025.1% during the third quarter. International Assets Investment Management LLC now owns 738,984 shares of the insurance provider’s stock valued at $2,340,660,000 after buying an additional 738,701 shares in the last quarter. FMR LLC grew its stake in Humana by 23.4% during the 3rd quarter. FMR LLC now owns 3,388,859 shares of the insurance provider’s stock valued at $1,073,387,000 after acquiring an additional 643,291 shares in the last quarter. Thrivent Financial for Lutherans increased its holdings in shares of Humana by 55.6% in the 3rd quarter. Thrivent Financial for Lutherans now owns 600,317 shares of the insurance provider’s stock valued at $190,145,000 after purchasing an additional 214,535 shares during the period. Retirement Systems of Alabama lifted its position in shares of Humana by 735.9% in the fourth quarter. Retirement Systems of Alabama now owns 219,002 shares of the insurance provider’s stock worth $55,563,000 after purchasing an additional 192,801 shares in the last quarter. Finally, Pzena Investment Management LLC boosted its holdings in shares of Humana by 8.1% during the third quarter. Pzena Investment Management LLC now owns 2,506,250 shares of the insurance provider’s stock worth $793,830,000 after purchasing an additional 187,903 shares during the period. 92.38% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity

In related news, insider Timothy S. Huval sold 3,703 shares of the company’s stock in a transaction on Tuesday, December 31st. The shares were sold at an average price of $256.26, for a total transaction of $948,930.78. Following the completion of the transaction, the insider now directly owns 8,181 shares in the company, valued at $2,096,463.06. This represents a 31.16 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 0.32% of the stock is owned by company insiders.

Humana Price Performance

Shares of NYSE:HUM opened at $266.91 on Tuesday. The company has a market cap of $32.14 billion, a price-to-earnings ratio of 23.64, a PEG ratio of 2.11 and a beta of 0.56. The business has a 50 day moving average price of $274.21 and a 200 day moving average price of $297.52. The company has a quick ratio of 1.76, a current ratio of 1.76 and a debt-to-equity ratio of 0.67. Humana Inc. has a twelve month low of $213.31 and a twelve month high of $406.46.

Analyst Upgrades and Downgrades

Several research analysts have weighed in on the stock. Bank of America upgraded shares of Humana from an “underperform” rating to a “neutral” rating and upped their price objective for the company from $247.00 to $308.00 in a research note on Wednesday, November 6th. Morgan Stanley increased their price objective on Humana from $288.00 to $301.00 and gave the stock an “equal weight” rating in a report on Tuesday, December 17th. Wells Fargo & Company lowered their target price on Humana from $387.00 to $290.00 and set an “overweight” rating on the stock in a research note on Monday, November 4th. TD Cowen raised their price target on Humana from $261.00 to $268.00 and gave the stock a “hold” rating in a research note on Monday, November 4th. Finally, Truist Financial boosted their price target on Humana from $260.00 to $290.00 and gave the company a “hold” rating in a research note on Monday, January 6th. Nineteen research analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Hold” and an average target price of $297.68.

About Humana

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.